From APIs to Innovative Drugs: Shengnuo Biopharm's Full-Industry-Chain Layout in Peptide Therapeutics

On the dynamic land of Dayi, Chengdu, a high-tech enterprise dedicated to the R&D and production of peptide drugs is leading China's peptide pharmaceutical industry to the world with remarkable momentum. Chengdu Shengnuo Biopharm Co., Ltd. (hereinafter referred to as "Shengnuo Biopharm," stock code: 688117), since its establishment in 2001, has been deeply cultivating the peptide field and has grown into a domestic leader in peptide API (Active Pharmaceutical Ingredient) manufacturing, integrating R&D, production, and sales.

Technology-Driven Enterprise, Building Core Advantages Across the Full Industry Chain

Shengnuo Biopharm started with an exceptionally strong foundation. The company's founder, Mr. Wen Yongjun, has been dedicated to peptide drug R&D since 1991 and led the development of the first three peptide drugs approved by China's NMPA—Thymopentin, Thymalfasin, and Somatostatin—filling the domestic gap in peptide therapeutics. Leveraging deep technical expertise, Shengnuo Biopharm has mastered a number of proprietary core technologies in peptide synthesis and modification, including long-chain peptide coupling technology, large-scale production technology for single-ring cyclic peptides, and synthesis technology for multiple disulfide cyclic peptides. These capabilities have successfully resolved technical bottlenecks in the large-scale production of multiple peptide APIs.

As a state-level "Specialized, Refined, Unique, and Innovative" enterprise and a National High-Tech Enterprise, Shengnuo Biopharm possesses key technologies for the large-scale production of over 50 peptide drugs that are already on the market both in China and internationally, with single-batch yields reaching the kilogram level. The company has passed the U.S. FDA inspection with "zero deficiencies" and obtained official certifications from South Korea, Mexico, and other countries, demonstrating that its quality management system meets internationally advanced standards.

Diversified Product Portfolio, Serving the Global Market

Shengnuo Biopharm has mastered the large-scale production technology for 15 API product varieties, of which 9 have obtained production approvals in China and 9 have received U.S. DMF filings (with 8 currently in active status). In addition, the company has secured 12 production approvals in China for 8 extended peptide formulation products. The product portfolio covers key therapeutic areas where peptide drugs play a vital role, including immunology, gastroenterology, antivirals, obstetrics & gynecology, diabetes, cardiovascular & cerebrovascular diseases, rare diseases, and orthopedics.

Several of the company's products hold leading positions in both domestic and international markets: Enfuvirtide for injection and Carbetocin injection are the first generic peptide drugs in China. High-synthesis-difficulty APIs such as Bivalirudin, Liraglutide, Thymalfasin, Icatibant, and Enfuvirtide have been exported to international markets including Europe, the Americas, India, and South Korea, with end customers comprising well-known pharmaceutical companies such as Fresenius, Aurobindo, Mylan, and Lupin.

Integrating Generics and Innovation, Striving for the "No. 1 Peptide Pharmaceutical Brand"

Shengnuo Biopharm has established a unique business model that integrates peptide APIs, formulations, and CDMO services for innovative drugs—a structure unparalleled in the industry. The company has provided pharmaceutical research services for over 40 innovative drug projects, with more than 20 peptide innovative drugs having entered clinical trial stages. Its clients include renowned biopharmaceutical companies such as Frontier Biotechnologies, Bio-Thera Solutions, and PegBio.

In terms of production capacity, the company operates two major API manufacturing bases in Dayi and Meishan. Upon completion of the new facilities, the annual production capacity will reach nearly 10 tons of peptide APIs, capable of meeting potential global market demand. In 2025, the company achieved operating revenue of RMB 741 million, a year-on-year increase of 62.57%, and a net profit of RMB 158 million, a year-on-year surge of 215.70%. All three core financial metrics reached historic highs.

Looking Ahead: Commitment to Innovation and Global Health

Looking to the future, Shengnuo Biopharm will continue to uphold its philosophy of "Independent Innovation, Serving the Nation and Benefiting the People." The company aims to strengthen its advantages in generic drugs, expand its CDMO service offerings, and focus on high-potential areas such as medications for chronic diseases. With a steadfast commitment, Shengnuo Biopharm is advancing steadily toward its vision of becoming the No. 1 peptide pharmaceutical brand in China, contributing China's strength to the global cause of human health.

Enterprise Contact Information

Address: Section 1, Gongye Avenue, Dayi County, Chengdu, Sichuan, China

ChemNet Shop: www.chemnet.com/ChinaSuppliers/53677/

Tel: +86-28-88203630;+86-13880038419

Email: info@snbiopharm.com